Table 1.
Participants clinico-demographic data
| Variable | All n = 284 | HIV+/ PTB+ n = 145 | HIV+/ PTB− n = 139 | p - value |
|---|---|---|---|---|
| Age median(IQR) | 38 (32–46) | 38 (32–44) | 38 (32–47) | 0.534 |
| Female | 142 (50) | 72 (49.6) | 70(50.4) | 0.893 |
| On cART | 140(49.3) | 62 (47.3) | 78(56.1) | 0.138 |
| Duration of cART (months) Median(IQR) | 21 (1–58) | 10 (1–48) | 32 (9–58) | 0.076 |
| Alive at Week-8 Follow-up | 191(70.7) | 90(62.1) | 101(72.7) | 0.057 |
| Duration of Hospital Stay (Days) Median(IQR) | 5(3–8) | 4(3–7) | 5(4–10) | < 0.001 |
| CD4 T-lymphocytes count (cells/μL) median(IQR) | 54(18–144) | 41 (14–110) | 86(25–220) | < 0.001 |
| BMI Median(IQR) | 19.2(17.0–21.5) | 19.1(16.6–20.8) | 19.2(17.3–21.8) | 0.222 |
| BMI ≤18.5 | 95(33.4) | 48(33.1) | 47(33.8) | 0.901 |
| On efavirenz based regimen | 109(38.3) | 48(33.1) | 61 (43.9) | 0.061 |
| Haemoglobin g/dl mean(SD) | 9.2(2.8) | 8.6(2.4) | 9.6(3.0) | 0.030 |
Key: n = number of participants in category, IQR interquartile range, SD standard deviation, BMI Body Mass Index, cART combination Antiretroviral therapy, All values are stated as n(%) unless indicated otherwise. p-values of ≤ 0.05 were considered statistically significant